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Background: Vitamin D receptor activators reduce albuminuria, and may improve survival in chronic kidney disease
(CKD). Animal studies suggest that these pleiotropic effects of vitamin D may be mediated by suppression of renin.
However, randomized trials in humans have yet to establish this relationship.
Methods: In a randomized, placebo-controlled, double-blinded crossover study, the effect of oral paricalcitol (2 μg/
day) was investigated in 26 patients with non-diabetic, albuminuric stage III-IV CKD. After treatment, plasma
concentrations of renin (PRC), angiotensin II (AngII) and aldosterone (Aldo) were measured. GFR was determined by
51Cr-EDTA clearance. Assessment of renal NO dependency was performed by infusion of NG-monomethyl-L-
arginine (L-NMMA). Albumin excretion rate (AER) was analyzed in 24-h urine and during 51Cr-EDTA clearance.
Results: Paricalcitol did not alter plasma levels of renin, AngII, Aldo, or urinary excretion of sodium and potassium.
A modest reduction of borderline significance was observed in AER, and paricalcitol abrogated the albuminuric
response to L-NMMA.
Conclusions: In this randomized, placebo-controlled trial paricalcitol only marginally decreased AER and did not
alter circulating levels of renin, AngII or Aldo. The abrogation of the rise in albumin excretion by paricalcitol during
NOS blockade may indicate that favourable modulation of renal NO dependency could be involved in mediating
reno-protection and survival benefits in CKD.
Trial registration: ClinicalTrials.gov identifier: NCT01136564
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Vitamin D receptor activators (VDRAs) have been used
in the management of secondary hyperparathyroidism in
chronic kidney disease (CKD) for several decades [1]. Se-
lective VDRAs such as paricalcitol effectively suppress
PTH secretion, but have less impact on gastrointestinal
calcium and phosphate uptake compared with calcitriol.
Recently, it has been shown that VDRAs reduces albu-
minuria in CKD and may slow down progression of
renal damage and dysfunction [2-4]. Conclusions from
animal studies strongly suggest that vitamin D’s pro-
posed reno-protective properties may be mediated by* Correspondence: tlarsen@beaconhealthsystem.org
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reproduction in any medium, provided the orsuppression of the renin-angiotensin system (RAS) [5-7].
Additionally, calcitriol has been shown to reduce renal
inflammation [8], and preserve the glomeruli slit
diaphragm by abrogating loss of nefrin [9]. The integrity
of the glomerular filtration barrier is highly dependent
on nitric oxide (NO) [10], and acute blockade of the
NO synthase (NOS) by NG-monomethyl-L-arginine
(L-NMMA) provokes albuminuria in humans [11].
Animal studies indicate that modulation of the NO sys-
tem may represent another pathway by which vitamin D
reduces albuminuria [12,13].
Despite pharmacological advances in the treatment of
renal disease, the progressive nature of CKD still war-
rants new strategies to preserve kidney function. VDRAs
are novel candidates, although their reno-protective
properties in man remain to be elucidated. In theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crossover trial, we wanted to test the hypothesis that
paricalcitol decreases albuminuria in CKD by suppress-
ing plasma renin. Moreover, we hypothesized that
paricalcitol modulates renal NO bioavailability. This was
investigated by employing acute NOS inhibition by L-
NMMA. Hemodynamic and non-hemodynamic effects
of paricalcitol were assessed by measurement of 24-hour
ambulatory BP (24-h BP), arterial stiffness, GFR,
albumin excretion rate, renal sodium and potassium
excretion, and plasma concentrations of angiotensin II
(AngII), aldosterone (Aldo), vasopressin (AVP), brain





Subjects were recruited from the nephrology outpatient
unit at Holstebro Hospital, Denmark between June 2010
and August 2011. Inclusion criteria were age >18 years,
stage III-IV CKD (eGFR: 15–59 ml/min) and micro- or
macroalbuminuria (u-alb >30 mg/l). Exclusion criteria
were diabetes mellitus (hbA1c ≥6.5%), cardiac arrhythmias,
malignant disease, immunosuppressive treatment, alcohol
abuse (>24 grams per day), p-albumin <25 mmol/l,
hypercalcemia (p-Ca++ >1.32 mmol/l) and office BP >170/
105 mmHg. Withdrawal criteria were development of
exclusion criteria, medication changes, withdrawal of
consent and poor compliance. Sample size was calculated
using PRC as primary endpoint. With a significance level
of 5% and an 80% power to detect a 10 pg/ml difference
in PRC, a total of 24 subjects were needed in this cross-
over study.
Ethics
The study protocol was approved by the Danish Medi-
cines Agency (Eudract no 2009-017619-14), the Regional
Committee on Biomedical Research Ethics (journal
no M-20090236), and The Danish Data Protection
Agency. The trial was registered at www.clinicaltrials.gov
(ClinicalTrial identifier: NCT01136564) and carried out
in accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient.
Design
This was a randomized, placebo-controlled, double blinded,
crossover study. Participants were consecutively allocated
to treatment via computer-generated randomization using
blocks of six, and received paricalcitol capsules and
matching placebo in random order. After inclusion, each
patient entered a four-week run-in phase where any treat-
ment involving vitamin D or RAS inhibitors were
discontinued. If needed, amlodipine, a diuretic, metoprololor minoxidil was added to control hypertension. No
changes in BP medication were made after the run-in phase
of the study. Patients took the study drug orally as two
capsules daily for two periods of six weeks with a two-week
intercalated washout period. Safety visits were conducted
every two weeks to monitor p-Ca++, BP, compliance and
potential side effects.
Study drug
Paricalcitol (1 μg per capsule) and placebo (Abbott La-
boratories, IL, USA) were taken orally as two capsules
per day. The non-selective NOS inhibitor, L-NMMA
(Bachem, Germany), was dissolved in isotonic saline
solution.
Experimental procedure
Measurements were performed at the end of each six
week treatment period of which the last four days
encompassed intake of a standardized diet. The diet was
composed to fit energy requirements determined by
weight and level of physical activity at work, leisure and
workout. If the estimated energy requirement exceeded
9,500 kJ/day a large diet was given (11,000 kJ/day).
Otherwise a small diet (8,000 kJ/day) was given. The diet
consisted of three main and three in-between meals per
day, and contained 55% carbohydrates, 30% fat and 15%
protein. The sodium content was 130 mmol/day in the
larger diet and 95 mmol/day in the smaller. Fluid intake
was 35 ml water/kg/day, and no other liquids were
allowed during those four days.
An outline of each of the two examination days is
given in Additional file 1: Table S1. At 8 AM two in-
dwelling catheters for blood sampling and infusion of
51Cr-EDTA and L-NMMA were placed in cubital veins,
one in each arm. Subjects were water loaded with oral
tap water 175 ml every 30 minutes, and urine was col-
lected by voiding in the standing or sitting position.
Otherwise subjects were kept in supine position in a
quiet, temperature-controlled room (22-25°C). 51Cr-
EDTA was adjusted for weight and renal function, and
administered as a priming dose at 8:30 AM followed by
sustained infusion. Urine collected the first 60 minutes
after priming dose was not analyzed. At 11 AM an L-
NMMA bolus injection of 4.5 mg/kg was given, followed
by continuous infusion at a rate of 3.0 mg/kg/hr for
60 minutes. Blood and urine samples were collected
every 30 min from 9:30 AM to 1 PM, and analyzed for
51Cr-EDTA, electrolytes, albumin and osmolality. The
three clearance periods from 9:30 AM to 11 AM were
pooled for analysis and used to define baseline. These
were followed by four 30 min clearance periods. For de-
termining hormone levels, blood samples were drawn at
11 AM (baseline), at noon (after 60 min of study drug
infusion), and at 1 PM (60 min after cessation of
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10.40 AM (baseline) and 11.40 AM.
Effect variables
The prespecified primary end point was plasma renin
concentration (PRC). Secondary effect variables were
urinary albumin excretion rate (AER), carotid-femoral
pulse wave velocity (PWV), Augmentation Index (AIx),
GFR, fractional excretion of sodium (FENa) and potas-
sium (FEK) urinary excreation of aquaporin 2 channels
(AQP2) and epithelial sodium channels (ENaCγ), FGF23,
and AngII, Aldo, BNP and AVP at baseline and during
NOS blockade.
Biochemical analyses
Blood samples for determination of vasoactive hormones
were taken on ice and centrifuged for 15 min at
3500 rpm and kept frozen at −80°C or −20°C until
assayed all at once. PRC was determined using an
immunoradiometric assay from CIS Bio International,
Gif-Sur-Yvette Cedex, France. Minimal detection level
was 1 pg/ml. The coefficients of variation were 0.9-3.6%
(intra-assay) and 3.7-5.0% (inter-assay) in the range of
4–263 pg/ml. AngII was extracted from plasma with C18
Sep-Pak (Water associates, Milford, MA, USA), and sub-
sequently determined by radioimmunoassay (RIA) as
previously described [14]. The antibody was obtained
from the Department of Clinical Physiology, Glostrup
Hospital, Denmark. Minimal detection level was 1.5 pg/
ml. The coefficients of variation were 12% (inter-assay)
and 8% (intra-assay). Aldo was determined by RIA using
a kit from Demeditec Diagnostics GmbH, Germany.
Minimal detection level was 25 pmol/l. The coefficients
of variation were 6.7-10.4% (inter-assay) and 7.5-9.5%
(intra-assay). AVP was extracted as Ang II and deter-
mined by radioimmunoassay14. The antibody against
AVP was a gift from Professor Jacques Dürr, Miami, Fl,
USA. Minimal detection level was 0.2 pmol/L. The
coefficients of variation were 13% (inter-assay) and 9%
(intra-assay).
Intact plasma levels of FGF23 were determined by a
sandwich ELISA (Immutopics Inc., CA, USA). The coef-
ficients of variation were 6% (inter-assay) and 4% (intra-
assay). Commercial chemiluminescens immunoassays
were used to analyze plasma concentrations of 25(OH)
D2 + D3 (Liaison, DiaSorin Inc., Saluggia, Italy) and BNP
(Architect, Abbott Laboratories, IL, USA).
Urine samples were kept frozen at −20°C until assayed.
u-AQP2 was measured by radioimmunoassay as previ-
ously described, and antibodies were raised in rabbits to
a synthetic peptide corresponding to the 15 COOH-
terminal amino acids in human AQP-2 to which was
added an NH2-terminal cystein for conjugation and af-
finity purification. Minimal detection level was 0.15 ng/tube. The coefficients of variation were 11.7% (inter-
assay) and 5.9% (intra-assay) [15]. u-ENaCγ was mea-
sured by radioimmunoassay as previously described, and
antibodies were raised in rabbits. Minimal detection
level was 48 pg/tube. The coefficients of variation were
14% (inter-assay) and 7.4% (intra-assay) [16].
Plasma and urinary osmolality were measured by
freezing-point depression (Advanced Model 3900
multisampling osmometer). Routine blood and urine
chemistry including a complete blood count, basic
metabolic panel, cholesterol, ionized calcium, iPTH,
phosphate, 25(OH)D2+3 as well as urinary albumin and
calcium concentrations, were immediately assayed at
the Department of Clinical Biochemistry.
Calculations
Free water clearance (CH2O) was determined according
to the formula CH2O = urine output (V) - osmolar clear-
ance (COSM). FENa and FEK were calculated according to
the formula FEx = (u ‐X * V/p ‐X)/GFR during the clear-
ance experiment and in 24-h urine according to the
formula FEx = (u ‐X * p ‐Crea)/(p ‐X * u ‐Crea).
Renal function
Glomerular filtration rate was measured using constant
infusion clearance technique with 51Cr-EDTA as a refer-
ence substance. Estimate GFR (eGFR) was calculated
using the MDRD formula.
Ambulatory BP measurement
24-h BP was measured (Kivex TM-2430, Hoersholm,
Denmark). BPs were recorded in the non-dominant
arm every 15 min during daytime and every 30 min
overnight.
Applanation tonometry
Carotid-femoral PWV and radial pulse wave analysis
(PWA) were obtained by a trained technician using
applanation tonometry (SphygmoCor CPV system®,
Atcor Medical, Sidney, Australia). Only duplicate record-
ings that met the minimum quality requirements were
included in the final analysis. Brachial BP used for PWA
was recorded by a semiautomatic, oscillometric device
(Omron 705IT, Japan). If the difference within a dupli-
cate BP recording exceeded 7 mmHg, the BP measure-
ment was repeated.
Statistical analysis
Differences between placebo and paricalcitol were com-
pared using Student’s paired t-test for parametric data,
and Wilcoxon’s Signed Rank test for non-parametric
data. Estimates are given as means ± SD unless stated
otherwise. The effect of L-NMMA on repeatedly mea-
sured variables was assessed by Friedman’s two-way
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sponse was analyzed by a general linear model (GLM)
for repeated measures with paricalcitol/placebo and time
as within-subject factors. Spearman’s rho was used for
correlation analyses. Statistical significance was defined
as p < 0.05. Statistical analyses were performed using
PASW version 18.0.0 (SPSS Inc.; Chicago, IL, USA).
Results
Demographics
Recruitment and demographics are given in Figure 1
and Table 1, respectively. Compliance with study medi-
cation assessed by pill count was 99.7% for placebo and
99.4% for paricalcitol. Five males were excluded from
analysis of clearance related variables due to inadequate
ability to empty the bladder. These subjects did not dif-
fer from the overall study population regarding age,
eGFR and baseline albuminuria.
The impact of paricalcitol on calcium metabolism
and FGF23
Paricalcitol reduced PTH and marginally increased con-
centrations of phosphate and Ca++ as well as 24-h urin-
ary calcium excretion (Table 2). One patient in the
paricalcitol group developed asymptomatic hypercalce-
mia after four weeks of treatment (Ca++: 1.43 mmol/l),
and the study drug was reduced to one capsule daily
with normalization of p-Ca++ at follow-up two weeks
later. Paricalcitol increased FGF23 by 46% (95%CI:
[21;71], p = 0.001). A weak positive correlation betweenFigure 1 Flowchart.changes in FGF23 and changes in p-phosphate was ob-
served (r = 0.40; p = 0.04). Likewise, changes in FGF23
correlated negatively with changes in PTH (r = −0.42;
p = 0.03).
The impact of paricalcitol on blood pressure and
arterial stiffness
Ambulatory BP and heart rate were not affected by
paricalcitol (Table 2). Similarly, no difference in PWV,
AIx and central BP estimated by applanation tonometry
were observed between placebo and paricalcitol. L-
NMMA infusion elicited a temporary increase in both
systolic and diastolic BP (Figure 2) as well as PWV (pla-
cebo: 0.4 ± 1.0 m/s; paricalcitol: 0.5 ± 0.8 m/s) and AIx
(placebo: 3.4 ± 2.7%; paricalcitol: 3.9 ± 5.5%). These ef-
fects were not altered by paricalcitol.
The impact of paricalcitol on albuminuria before and
after NOS inhibition
There was no significant difference in 24-h urinary albu-
min excretion between paricalcitol and placebo (−7%
[95%CI:-20;7] p = 0.12, Table 2). However, during the 90-
min baseline period of the clearance experiment
(Additional file 1: Table S1) AER was significantly re-
duced by 19% [95%CI:-31;-8] (p = 0.003) and UACR by
20% [95%CI:-30;-11] (p < 0.001) compared with placebo.
Figure 3 illustrates the changes in AER related to L-
NMMA infusion. During the first 30 minute period after
L-NMMA infusion was initiated, AER increased 22%
[95%CI:1;43] when patients had received placebo. On
Table 1 Patient demographics (n = 26)
Age, years (±SD) 61 ± 9
Male sex, no (%) 19 (73)
Smokers, no (%) 13 (50)
Body mass index, kg/m2 (±SD) 26.7 ± 4.6
Office blood pressure, mmHg (±SD) 136/83 ± 13/9
Medication, no (%)
Calcium channel blockers 20 (77)
Alpha blockers 1 (4)
Beta blockers 16 (62)
Minoxidil 7 (27)
Loop diuretics 16 (62)








eGFR, ml/min/1.73 m2 (MDRD) 26 ± 11
p-Creatinine, μmol/l 231 ± 78
p-Ca++ 1.22 ± 0.05
p-Phosphate, mmol/l 1.19 ± 0.27
p-Cholesterol (total), mmol/l 5.0 ± 1.2
p-Hemoglobin, mmol/l 8.3 ± 0.8
p-Albumin, g/l 43 ± 3
u-Albumin, mg/l 169 [Interquartile range:
59;489]
P25(OH)D2+3, nmol/l 56 ± 21
Primary kidney disease, no (%)
Glomerulonephritis 6 (23)
Polycystic kidney disease 3 (12)
Chronic interstitial nephritis 2 (8)
Unknown* 15 (58)
*Renal biopsy deferred due to advanced stage of kidney disease on admission,
reduced kidney size on radiologic examination and absence of
nephrotic syndrome.
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paricalcitol treatment (0% [95%CI:-13;14], p = 0.02 be-
tween treatments).
The impact of paricalcitol on kidney function before
and after NOS inhibition
Compared with placebo, plasma creatinine increased
from 223 ± 88 to 243 ± 97 μmol/l (p = 0.004) after
paricalcitol. Estimated GFR (MDRD) decreased by 9 ±
11% from 29 ± 13 to 26 ± 12 ml/min (p < 0.001), 24-h
urine creatinine clearance by 7 ± 12% from 40 ± 17 to
37 ± 16 ml/min/1.73 m2 (p = 0.002) (Table 2), and 51Cr-EDTA clearance by 7 ± 14% from 26 ± 13 to 24 ± 12 ml/
min/1.73 m2 (p = 0.003). During the subsequent infusion
of L-NMMA, 51Cr-EDTA clearance, urine output and
CH2O were consistently lower after paricalcitol treat-
ment compared with placebo. However, the response
to L-NMMA was not affected by paricalcitol (Table 3).
The impact on paricalcitol on vasoactive hormones and
renal handling of sodium and potassium
Tables 3 and 4 summarize the effects of paricalcitol on
RAS and related variables at baseline and in relation to
L-NMMA infusion. Whereas plasma levels of renin and
AngII were not affected by paricalcitol, Aldo tended to
increase (Table 4). A decrease in plasma potassium was
also observed, and the relative changes in Aldo corre-
lated positively with relative changes in FEK (r = 0.65,
p = 0.002). Paricalcitol did not alter FENa or the urinary
excretion of ENaCγ and AQP2 (Table 3).
Discussion
The main objective of this randomized, placebo-
controlled, crossover trial was to investigate the effects
of paricalcitol on PRC with employment of diet
standardization and a run-in phase where RAS inhibitors
were discontinued. We found no significant effect of
paricalcitol on PRC and 24-h AER, although AER during
51chrom-EDTA clearance was significantly lower in the
paricalcitol group. Additionally, this study found that
paricalcitol 1) blunted the albuminuric response to NOS
inhibition, 2) increased serum FGF23 and 3) reduced
GFR measured by 51Cr-EDTA clearance.
In the present trial, paricalcitol treatment did not
affect plasma concentrations of renin and AngII signifi-
cantly. Aldo tended to increase which may have been
caused by slightly higher plasma potassium during
paricalcitol treatment. Suppression of RAS is thought to
be an important mediator of the reno-protective proper-
ties of VDRAs in CKD [17]. Most of our current know-
ledge regarding the relationship between vitamin D and
RAS originates from animals studies, where it has been
shown that calcitriol down-regulates renin expression in-
dependently from PTH and calcium levels [18]. Renin
expression is highly elevated in VDR null mice, which
leads to systemic hypertension, cardiac hypertrophy and
heart failure [19]. Although an inverse relationship be-
tween 1,25(OH)2D and PRC has been documented in
humans [20], prospective clinical trials have not con-
firmed this relationship satisfactorily. The results of a
descriptive study of 17 children and young adults with
hereditary vitamin D resistant rickets were remarkable,
as none of the patients had hypertension, left ventricular
hypertrophy or PRA elevation [21]. In the VITAL study
paricalcitol did not suppress PRA in patients with dia-
betic nephropathy, although albuminuria was reduced
Table 2 Effect of paricalcitol on calcium metabolism, blood pressure and 24-h albumin excretion in patients with stage
III-IV CKD and albuminuria (n = 26)
Placebo Paricalcitol P value
Calcium and phosphate metabolism
p-iPTH (pmol/l) 11.80 [8.82;14.93] 6.44 [3.11;8.78] <0.001
p-Ca++ (mmol/l) 1.22 [1.16;1.25] 1.23 [1.19;1.28] 0.01
p-phosphate (mmol/l) 1.18 [0.97;1.35] 1.29 [1.10;1.59] 0.02
p-ALP (U/l) 66 [58;91] 65 [51;82] <0.001
p-25(OH)D (nmol/l) 58 [39;72] 59 [50;69] 0.26
p-FGF23 (pg/ml) 28.5 [19.7;46.7] 32.3 [27.2;67.1] 0.002
u-Ca (mmol/24-h) 0.78 [0.39;2.03] 1.24 [0.66;3.04] 0.006
u-Ca/cr (mmol/mmol) 0.06 [0.03;0.15] 0.12 [0.06;0.22] 0.005
24-h ambulatory blood pressure and arterial stiffness
24-h SBP (mmHg) 133 ± 11 133 ± 10 0.92
24-h DBP (mmHg) 81 ± 7 81 ± 7 0.94
24-h heart rate (bpm) 67 ± 9 68 ± 9 0.15
PWV (m/s) 7.9 ± 1.3 7.6 ± 1.3 0.21
AIx@75 (%) 21 ± 13 19 ± 11 0.30
Central SBP (mmHg) 132 ± 12 130 ± 13 0.34
Central DBP (mmHg) 82 ± 7 82 ± 6 0.97
Creatinine clearance and albumin excretion in 24-h urine
Urine output (ml/24-h) 2805 [2430;3160] 2794 [2270;3210] 0.43
Creatinine clearance (ml/min/1.73 m2) 36 [28;51] 32 [27;46] 0.005
u-alb (mg/24-h) 665 [80;2598] 590 [146;2025] 0.12
UACR (mg/g) 507 [80;1523] 388 [104;1109] 0.34
Values are presented as medians with 25 and 75 percentiles in brackets, or as means ± SD. iPTH Intact parathyroid hormone, Ca++ Ionized calcium, ALP Alkaline
phosphatase 25(OH)D, 25-hydroxyvitamin D; FGF23, fibroblast growth factor 23; u-Ca/cr, urinary calcium-creatinine ratio; PWV, carotid-femoral pulse wave velocity;
AIx@75, central augmentation index standardized to a heart rate of 75 beats per minute (bpm); UACR, urinary albumin-creatinine ratio. P values represent the
probability of a difference between treatments.
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tion of renin expression remains to be established in
humans, and ultimately raises the question whether a
causal relationship between vitamin D and renin secre-
tion exists. Eraranta et al. proposed that an answer may
lie in the timing of vitamin D treatment in relation to
renal injury [22]. In 5/6 nephrectomized rats, Freundlich
et al. documented a significant suppression of renin-
angiotensin genes when paricalcitol was initiated a few
days after surgery [5]. On the contrary, instituting
paricalcitol treatment 15 weeks after 5/6 nephrectomy
did not cause any changes in RAS components [22,23].
The latter animal model of CKD may more accurately
resemble the state of chronic renal insufficiency in man.
Twenty-four-hour urinary albumin excretion was not
significantly reduced after paricalcitol, although the de-
crease in AER during the 90-min baseline period of the
clearance experiment was more pronounced and statisti-
cally significant. Thus, our results do not unambiguously
confirm the findings from precious studies regarding the
effects of paricalcitol on albuminuria [2-4].Glomerular permeability to albumin is highly de-
pendent on NO [10], which led us to explore the effect
of paricalcitol on renal NO dependency by acute infu-
sion of L-NMMA, a non-selective NOS inhibitor. The
L-NMMA dose chosen in our study was based on a pre-
liminary dose–response trial, in which hemodynamic
and renal effects of L-NMMA were characterized [24].
In the present study, L-NMMA caused an acute increase
AER when patients had received placebo. Paricalcitol, on
the other hand appeared to blunt this increase in albu-
minuria, which could be caused by either prevention of
the NOS inhibitor mediated increase in glomerular per-
meability, or by increased albumin reuptake. Tubular re-
absorption of albumin involves cubilin and megalin [25],
but the role of vitamin D in regulation of these receptors
has not yet been elucidated. In patient populations prone
to endothelial dysfunction, NOS blockade provokes al-
buminuria [11]. Moreover, flow mediated vasodilation
correlates to the degree of albuminuria [26]. Endothelial
NOS (eNOS) is expressed in endothelial cells, including
those of the kidney. This enzyme plays an important role
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trated by the progressive renal failure observed in eNOS
knock-out mice [28]. A decrease in endothelial and renal
NO production in CKD has been suggested to play a pri-
mary role in progression of kidney disease [19]. Little is
known about the direct effects of vitamin D on renal
NO bioavailability, although a few studies have indicated
that vitamin D may play a role in the regulation of renal
NO generation. In uremic rats paricalcitol restored
eNOS deficiency [12], and calcitriol increased NO pro-
duction in cultured endothelial cells [13]. Thus, it seems
plausible that selective VDRAs may reduce proteinuria
through favourable modulation of the NO system. How-
ever, the results from the current trial do not have very
strong statistical confidence, and should be interpreted
with caution.
Our study showed a marked rise in FGF23 after
paricalcitol treatment, which is consistent with previous
studies of VDRA therapy in both predialysis [29] and
dialysis patients [30]. In CKD, elevated FGF23 has been
associated with increased cardiovascular mortality, and
the rise in FGF23 in early stages of CKD is believed to
be a main contributor to the decline in vitamin D levels
through the induction of CYP24A1 mediated degrad-
ation [31,32]. Whether FGF23 is truly an independent
risk factor or merely a marker of other abnormalities in
CKD remains to be established.
Although this study was not primarily designed to in-
vestigate the effects of paricalcitol on GFR, we found a
modest but statistically significant 3 ml/min/1.73 m2
decline in 51Cr-EDTA clearance after six weeks ofFigure 2 Effect of L-NMMA on systolic and diastolic blood pressure (B
infusion continued until 60min. P-value represents the effect of paricalcitol v
measures (n = 26).paricalcitol treatment compared with placebo. Rela-
tively, the decrease in creatinine based eGFR was larger
than the decrease in clearance based GFR measure-
ments. Activated vitamin D compounds have long been
known to increase plasma creatinine [33-37]. Hitherto
alterations in creatinine based estimations of GFR have
been attributed to increased tubular secretion of cre-
atinine [37] as well as musculoskeletal effects of vita-
min D in patients with uremic myopathy [34]. Inulin
clearance in eight [37] and ten patients [34] did not
yield any significant changes in true GFR despite in-
creases in creatinine. The effect of paricalcitol on GFR
was specifically investigated in a study of 16 patients
with CKD stage III-IV [33]. In this study, seven days of
oral paricalcitol caused a reversible increase in plasma
creatinine and 24-h urinary creatinine excretion with-
out reducing iothalamate or creatinine clearance sig-
nificantly. The authors documented an initial decrease
in serum urea nitrogen and urea excretion rate, which
may suggest an initial anabolic effect of paricalcitol.
Preliminary results from a yet unpublished randomized,
placebo controlled study in 45 patients with type 1
diabetes and nephropathy did not show any significant
decrease in GFR measured by 51Cr-EDTA clearance,
although creatinine based eGFR was significantly lower
after 12 weeks of paricalcitol treatment (Joergensen C,
Tarnow L, Goetze JP, Rossing P. Vitamin D analogue
therapy, cardiovascular risk and kidney function in
type 1 diabetic patients with diabetic nephropathy – a
randomized trial. 2012. Personal Communication. Cited in
agreement with the authors). These studies found smallP). L-NMMA bolus injection was administered at 0min, and sustained
ersus placebo assessed by a general linear model for repeated
Table 3 The effect of L-NMMA on GFR and renal handling of sodium and potassium after six weeks of paricalcitol
treatment in patients with stage III-IV CKD and albuminuria (n = 21)
Baseline 30 min 60 min 90 min 120 min PWithin PBetween
GFR (51Cr-EDTA clearance)
Placebo 26.3 ± 13.3 22.8 ± 10.9 24.2 ± 11.1 26.0 ± 11.7 27.8 ± 11.5 0.68 0.31
Paricalcitol 23.6 ± 11.5* 20.3 ± 9.7 22.5 ± 10.9 22.5 ± 12.0 23.9 ± 12.8 0.89
Urine output (ml/min)
Placebo 4.5 ± 2.1 3.1 ± 1.3 3.4 ± 1.2 3.6 ± 1.1 4.0 ± 1.8 0.02 0.15
Paricalcitol 3.4 ± 1.5* 2.4 ± 0.9 2.8 ± 1.2 3.1 ± 1.1 3.7 ± 1.5 0.01
Free water clearance (ml/min)
Placebo 1.7 ± 1.7 1.6 ± 1.4 1.1 ± 0.9 1.3 ± 0.9 1.5 ± 1.0 0.65 0.16
Paricalcitol 0.8 ± 1.0* 0.8 ± 1.0 0.7 ± 0.7 1.0 ± 0.9 1.3 ± 0.9 0.27
FENa (%)
Placebo 5.9 ± 4.3 4.7 ± 3.4 4.4 ± 3.1 4.2 ± 2.8 4.1 ± 2.7 0.37 0.54
Paricalcitol 5.9 ± 4.5 4.4 ± 3.7 4.4 ± 3.4 4.6 ± 4.1 4.6 ± 4.0 0.73
FEK (%)
Placebo 85 ± 95 67 ± 70 62 ± 62 58 ± 51 55 ± 45 0.61 0.74
Paricalcitol 92 ± 96 71 ± 65 67 ± 58 66 ± 55 63 ± 50 0.63
u-AQP2 (ng/hr)
Placebo 99 ± 37 71 ± 29 77 ± 34 80 ± 37 87 ± 51 0.16 0.67
Paricalcitol 100 ± 35 71 ± 30 74 ± 29 75 ± 32 75 ± 31 0.03
u-ENaCγ (ng/hr)
Placebo 9.6 ± 7.7 - 8.8 ± 7.8 - 9.8 ± 9.0 0.92 0.32
Paricalcitol 10.3 ± 5.3 - 8.2 ± 2.3 - 8.8 ± 3.7 0.21
Values are means ± SD. L-NMMA, NG-monomethyl-L-arginine; FENa, fractional excretion of sodium; FEK, fractional excretion of potassium; AQP2, aquaporin 2
channels; ENaCγ, gamma fraction of epithelial sodium channels. L-NMMA infusion was sustained for 60 minutes. Pwithin represents the probability of an effect of
NOS inhibition after each treatment assessed by one-way ANOVA. Pbetween represents the probability that paricalcitol alters the response to L-NMMA assessed by
a general linear model for repeated measures with treatment as factor.
* = p < 0.05 vs. placebo at baseline.
Figure 3 Effect of L-NMMA on albumin excretion rate. A) Mean albumin excretion rate in placebo (closed circles) and paricalcitol (open
circles) at baseline (average for 3 periods of 30 minutes) and during nitric oxide synthase inhibition (NOSi). B) Mean changes in albumin excretion
rate ± SEM at baseline and during NOSi. L-NMMA was continuously infused for 60 minutes. Within differences in each group were tested by
Friedman’s two-way ANOVA, and comparisons between placebo and paricalcitol were made for each point in time by Wilcoxon’s signed rank test
(*p < 0.05, **p < 0.005) (n = 21).
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Table 4 The effect of L-NMMA on components of the renin-angiotensin system and plasma levels of sodium and
potassium after six weeks of paricalcitol treatment (n = 26)
Baseline 60 min 120 min PWithin PBetween
PRC (pg/ml)
Placebo 10.4 [6.1;23.6] 10.1 [6.1;18.8] 8.2 [6.8;17.1] 0.02 <0.01 0.31
Paricalcitol 10.9 [6.4;25.2] 8.4 [5.7;18.3] 8.9 [6.5;19.3]
p-AngII (pg/ml)
Placebo 5.0 [8.0;12.0] 6.5 [4.0;12.0] 7.5 [5.0;9.0] 0.01 0.17
Paricalcitol 8.0 [5.0;15.0] 7.0 [5.0;12.0] 8.0 [4.5;12.0] <0.01
p-Aldo (pmol/l)
Placebo 287 [152;607] 376 [180;663] 302 [161;520] <0.01 0.24
Paricalcitol 335 [187;619] 346 [200;742] 282 [165;590] <0.01
p-K (mmol/l)
Placebo 4.0 [3.7;4.4] 3.9 [3.7;4.4] 3.9 [3.7;4.4] 0.96 0.19
Paricalcitol 3.8 [3.6;4.2]* 3.7 [3.6;4.2] 3.8 [3.6;4.2] 0.80
p-Na (mmol/l)
Placebo 138 [136;140] 138 [136;138] 137 [135;140] 0.76 0.33
Paricalcitol 138 [136;140] 138 [136;140] 138 [136;140] 0.33
p-BNP (pmol/l)
Placebo 8.1[4.4;19.5] - -
Paricalcitol 7.5[4.8;14.3] - -
p-AVP (pg/ml)
Placebo 0.5 [0.4;0.7] - -
Paricalcitol 0.5 [0.4;0.7] - -
Values are medians with 25 and 75 percentiles in brackets. L-NMMA, NG-monomethyl-L-arginine; PRC, plasma renin concentration; AngII, angiotensin II; Aldo,
aldosterone; K, potassium; Na, sodium; BNP, brain natriuretic peptide; AVP, vasopressin. L-NMMA infusion was sustained for 60 minutes. Pwithin represents the
probability of an effect of NOS inhibition after each treatment assessed by Friedman’s ANOVA. Pbetween represents the probability that paricalcitol alters the
response to L-NMMA assessed by a general linear model for repeated measures with treatment as factor.
* = p < 0.05 vs. placebo at baseline.
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In the Primo trial, both creatinine and cystatin C based
estimations of GFR were significantly reduced after 48 weeks
of paricalcitol36. If vitamin D reduces albuminuria through
mechanisms similar to ACE inhibitors, the reduction in
creatinine and cystatin C base GFR calculations may
reflect a true decline in GFR, which will have important
implications for the management of CKD.
During baseline of the clearance experiment where pa-
tients underwent water loading, urine output and free
water clearance were lower after paricalcitol. This was
not accompanied by any significant changes in FENa,
FEK, AVP, BNP or urinary excretion of ENaCγ and
AQP2 channels, reflecting unaltered net tubular trans-
port of sodium and water. The reduction in GFR may
explain the decreased urine output and in turn be re-
sponsible for part of the reduction in AER.
To our knowledge this is the first study to document
the renal and vascular response to NOS inhibition in
vitamin D treated patients. Other strengths include the
randomized, double blinded, placebo-controlled design,
24-h BP monitoring, and the employment of diet andfluid standardizations. Limitations include small sample
size, short treatment duration, and the potential for
pharmacodynamic carry-over effects of paricalcitol.
For ethical reasons antihypertensive medication was
maintained. In order to minimize the effects of agents
directly influencing RAS, ACE inhibitors and AngII re-
ceptor blockers were discontinued and antihypertensive
medication kept unchanged during the study. However,
other medications such beta-blockers, potassium sparing
diuretics and calcium receptor antagonists inevitably
affect RAS activity as well. Furthermore, the discontinu-
ation of RAS inhibitors and slightly uneven gender
distribution may limit the generalizability of the results.
Conclusion
In conclusion, this study did not provide evidence that
paricalcitol suppresses circulating components of RAS in
patients with albuminuric stage III-IV CKD. Paricalcitol
reduced AER during the clearance experiment but not
in 24-h urine, and appeared to abrogate the proteinuric
response to NOS inhibition. Thus, it is possible that
paricalcitol may decrease albuminuria through RAS
Larsen et al. BMC Nephrology 2013, 14:163 Page 10 of 11
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and favourable modulation of the NO system.
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